Clinical Trial Update: ALN-APOC3 in Adult Participants With Dyslipidemia [Phase 1]

View source ↗

Summary

Phase 1 trial of ALN-APOC3 in adults with dyslipidemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• ALN-APOC3

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED